TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24831577
Drug: Low-dose rosuvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rosuvastatin (placebo before treatment plus 10 mg maintenance for 7 days)
Study: 30552406
Drug: Low-dose rosuvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rosuvastatin
Study: 16118813
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to prescribed antiretroviral therapy
Study: 10395118
Drug: Limited Sampling
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Limited Sampling Model (LSM) for Drug A
Study: 10395118
Drug: Limited Sampling
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Limited Sampling Model (LSM) for Drug B
Study: 26785220
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg GSK2586184 twice daily
Study: 26785220
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg GSK2586184 twice daily
Study: 26785220
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg GSK2586184 twice daily
Study: 15525879
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg/day)
Study: 17323185
Drug: Risedronate (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (2.5 mg/day)
Study: 7959995
Drug: Diuretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic therapy (Group III)
Study: 7959995
Drug: No diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No diuretic therapy (Group II)
Study: 2884723
Drug: Salazosulfapyridine (SI)
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salazosulfapyridine (SI) at a dose of 2 g/day
Study: 28198205
Drug: 13 mg
Normalized name: hemin 313 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 mg / day total MCs
Study: 28198205
Drug: 27 mg
Normalized name: aspirin 227 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27 mg / day total MCs
Study: 26268815
Drug: secukinumab 10
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: secukinumab 10 mg/kg i.v. every 2 weeks until week 10
Study: 19808841
Drug: Strength-based skills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength-based skills training program for dementia caregiving dyads; specific details on dosage and duration not available.
Study: 10643835
Drug: Estrogen Replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen Replacement Therapy (ERT)
Study: 11044542
Drug: Alendronate Therapy
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate Therapy
Study: 1616967
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg twice daily for 7 days)
Study: 1889980
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or other antimigraine drugs
Study: 6647211
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose salbutamol given by domestic nebulizers
Study: 12217456
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Fluoxetine and CBT)
Study: 2159838
Drug: PCV chemotherapy
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCV chemotherapy (cisplatin 100 mg/m2, cyclophosphamide 600 mg/m2, vindesine 3 mg/m2)
Study: 453063
Drug: High-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber diet (18.0 g crude fiber)
Study: 453063
Drug: Low-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fiber diet (1.0 g crude fiber)
Study: 22718223
Drug: Baseline fasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline fasting glucose level of 6.1 mmol/L or more
Study: 22115000
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system patch wear times (9, 10, 11, and 12 hours per day)
Study: 26759138
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose aspirin (81 mg/day) plus folic acid (400 mcg/day)
Study: 26759138
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus folic acid (400 mcg/day)
Study: 14748874
Drug: Continuous somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous somatostatin infusion for 12 hours starting 30 minutes before ERCP
Study: 14748874
Drug: Bolus intravenous
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intravenous injection of somatostatin at the time of cannulation
Study: 14748874
Drug: Somatostatin groups
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin groups (both continuous infusion and bolus)
Study: 2713259
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel (Retin A)
Study: 1100302
Drug: Dexamethasone phosphate
Normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone phosphate (DP) intravenous administration at dosages ranging from 0.05 to 2.0 mg/kg
Study: 1100302
Drug: 4 mg/ml
Normalized name: valine 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/ml parenteral solution of DP
Study: 1100302
Drug: Experimental high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental high potency preparation of 24 mg/ml
Study: 24522306
Drug: Oral polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polio vaccine (OPV)
Study: 22122960
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of beta-carotene, vitamins C and E, and magnesium
Study: 389419
Drug: Glucose-insulin-potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (GIK) infusion
Study: 10209349
Drug: Sumatriptan nasal
Normalized name: SUMAtriptan nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan nasal spray 20 mg
Study: 10209349
Drug: Sumatriptan nasal
Normalized name: SUMAtriptan nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan nasal spray 10 mg
Study: 9673807
Drug: Sumatriptan nasal
Normalized name: SUMAtriptan nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan nasal spray (both dosages)
Study: 7633535
Drug: High-cost antibiotics
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-cost antibiotics (amoxicillin plus clavulanate potassium, cefaclor, or cefixime) for persistent middle ear effusions
Study: 7633535
Drug: Oral decongestants
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral decongestants (alone or in combination with other therapy) at the 6-week visit
Study: 2755214
Drug: Potassium alone
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium alone (2 g potassium chloride daily)
Study: 2755214
Drug: Potassium and
Normalized name: Potassium and/or potassium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium and magnesium combined supplementation (2 g potassium and 1 g magnesium daily)
Study: 29231588
Drug: Acupoint catgut
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint catgut embedding therapy applied at bilateral Tianshu (ST 25), Changqiang (GV 1), bilateral Chengshan (BL 57) and Tigangxue (Extra), once a week for 4 weeks.
Study: 29231588
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication with 0.2% nitroglycerin ointment, applied externally on the wound, twice daily for 4 weeks.
Study: 21515290
Drug: Metoprolol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol monotherapy
Study: 21515290
Drug: Combined metoprolol
Normalized name: metoprolol and thiazides, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined metoprolol and felodipin therapy
Study: 9093709
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus adjuvant chemotherapy
Study: 17987285
Drug: Voriconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (400 mg twice on the first day and 200 mg twice on the second day)
Study: 17112806
Drug: Terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (250 mg once daily for 3 days)
Study: 17112806
Drug: Control (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (20 microg/kg intravenous alfentanil without pretreatment)
Study: 15253849
Drug: Real qi
Normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real qi therapy
Study: 3307093
Drug: Human chorionic
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human chorionic gonadotropins (HCG, 5,000 IU I.M. twice per week)
Study: 30572894
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g krill oil powder
Study: 25124503
Drug: Parental involvement
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental involvement in children's anxiety treatment
Study: 21905086
Drug: tolterodine 4
Normalized name: tolterodine 4 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine 4 mg long‐acting (LA)
Study: 17124621
Drug: escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram 20 mg + placebo
Study: 17092965
Drug: escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram 20 mg + ketanserin 50 mg
Study: 12552952
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of 5-FU for 5 days at a dose of 320 mg/m2 (CIV group, n = 6)
Study: 12552952
Drug: Bolus intravenous
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intravenous injection of 5-FU for 5 days at a dose of 320 mg/m2 (bolus group, n = 8)
Study: 2576666
Drug: Carvedilol 50
Normalized name: carvedilol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 50 mg once daily
Study: 17851827
Drug: Amine fluoride
Normalized name: triethylene amine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine fluoride gel (4000 ppm F)
Study: 16208800
Drug: PC 7000
Normalized name: POLYETHYLENE GLYCOL 7000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC 7000 toothbrush (Oral‐B ProfessionalCare 7000)
Study: 10695793
Drug: Tinidazole 50
Normalized name: tinidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 50 mg/kg single dose
Study: 8670601
Drug: Sulphasalazine (SSZ)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphasalazine (SSZ) 2.0 g/day
Study: 1662583
Drug: Nebulizer with
Normalized name: AeroNeb Go Nebulizer with Cable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer with 99mTc‐labelled colloidal human serum albumin (0.05 mg, 37 MBq)
Study: 26911887
Drug: Standard low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard low-dose protocol
Study: 18589019
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet with free virgin olive oil (1 L/week)
Study: 18589019
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet with free mixed nuts (30 g/day)
Study: 18589019
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (verbal instructions and leaflet recommending National Cholesterol Education Program Adult Treatment Panel III dietary guidelines)
Study: 15802772
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (menatetrenone, MK‐4) 45 mg/day
Study: 12575213
Drug: Sparfloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (200 mg once daily intravenous drip)
Study: 31912800
Drug: Istiratumab (2.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istiratumab (2.8 g intravenously every 2 weeks)
Study: 30894210
Drug: HF-LED-RL phototherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HF-LED-RL phototherapy at doses of 480 J/cm2 and 640 J/cm2
Study: 27484782
Drug: Mock therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mock therapy
Study: 22094316
Drug: Rapid rehydration
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid rehydration (60 mL/kg) with 0.9% saline over an hour
Study: 19015353
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of ritonavir
Study: 19015353
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of elvucitabine coadministered with 300 mg of ritonavir
Study: 9413102
Drug: Td +
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Td + full strength acellular pertussis vaccine (PT, 1 microgram/0.5 ml; FHA, 4 micrograms/0.5 ml)
Study: 9413102
Drug: Td +
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Td + half strength acellular pertussis vaccine
Study: 8480701
Drug: rhGH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH therapy (experimental group, n = 18)
Study: 31109255
Drug: Referral for
Normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral for treatment
Study: 31109255
Drug: Reasons for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reasons for seeking treatment
Study: 23868016
Drug: Barriers to
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barriers to treatment
Study: 31666270
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (15 mg/kg initially, followed by 7.5 mg/kg every 6 hours for 5 days)
Study: 19798634
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release acipimox capsules
Study: 16820995
Drug: Ambroxol (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (45 mg/day)
Study: 16820995
Drug: Carbocisteine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbocisteine (1500 mg/day)
Study: 20924615
Drug: Rebamipide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (300 mg/day)
Study: 10853205
Drug: Manual lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual lung hyperinflation treatment (patient positioning, suctioning, and manual lung hyperinflation)
Study: 10853205
Drug: Manual lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual lung hyperinflation treatment
Study: 10853205
Drug: Side-lying treatment
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side-lying treatment (patient positioning and suctioning)
Study: 8096526
Drug: Gepirone 2
Normalized name: gepirone 18.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone 2 mg/day increasing to 12 mg/day over 3 weeks
Study: 2427836
Drug: Celiprolol 200
Normalized name: celiprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 200 mg
Study: 2427836
Drug: Celiprolol 400
Normalized name: celiprolol 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 400 mg
Study: 29717839
Drug: Oral Testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Testosterone Undecanoate Capsules (TUC) combined with Qilin Pills (QLP) (6g, tid) for 3 months
Study: 29717839
Drug: Oral Testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Testosterone Undecanoate Capsules (TUC) (80 mg, qd) for 3 months
Study: 25788231
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (including balloon aortic valvuloplasty)
Study: 23733499
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (10 W class IV laser, 6.6 ± 1.3 J/cm²)
Study: 15325921
Drug: Alteplase and
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase and lanoteplase (thrombolytic therapy)
Study: 11230478
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus radiotherapy (CT/RT group)
Study: 4581080
Drug: Slow Sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow Sodium (sodium chloride preparation)
Study: 16523265
Drug: Sham point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham point treatment
Study: 8930778
Drug: Clemastine solution
Normalized name: clemastine Oral Solution
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clemastine solution (1, 2, and 4 mg)
Study: 8930778
Drug: Clemastine tablets
Normalized name: clemastine Oral Tablet
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clemastine tablets (1 mg and 2 mg)
Study: 8930778
Drug: Combination tablets
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablets (1 mg or 2 mg clemastine + 75 mg phenylpropanolamine)
Study: 10789958
Drug: Octreotide 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 0.3 mg daily (n = 9)
Study: 10789958
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide (HB) 60 mg daily (n = 9)
Study: 1524042
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (Induction chemotherapy followed by radiotherapy)
Study: 3542496
Drug: Colchicine therapy
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine therapy and Placebo
Study: 19117959
Drug: 30 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 U/kg unfractionated heparin bolus
Study: 19117959
Drug: 0 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 U/kg unfractionated heparin bolus
Study: 19117959
Drug: 80 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 U/kg unfractionated heparin bolus
Study: 12858654
Drug: RAM (ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAM (ranitidine + amoxicillin + metronidazole)
Study: 10216104
Drug: Leukocytosis over
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocytosis over 100 +/- 10(9)/L
Study: 31293259
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding
Study: 2613390
Drug: Vadocaine hydrochloride
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vadocaine hydrochloride tablet (30 mg t.i.d. for four days)
Study: 2613390
Drug: Vadocaine hydrochloride
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vadocaine hydrochloride solution
Study: 796755
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg chlorpromazine‐‐500 mg alpha‐methyldopa/day
Study: 796755
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg chlorpromazine‐‐750 mg alpha‐methyldopa/day
Study: 20391510
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (100 mg every other day)
Study: 16716319
Drug: Laser-assisted intracytoplasmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-assisted intracytoplasmic sperm injection (ICSI)
Study: 12920491
Drug: Quinine hydrochloride
Normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine hydrochloride (500 mg) alone
Study: 10867536
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folic acid daily for 3 months
Study: 6347746
Drug: Nimesulide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (200 mg/day)
Study: 30376860
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate
Study: 1287905
Drug: Intramuscular artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular artesunate
Study: 29570108
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg intravenous lidocaine over 5 min followed by 2 mg/kg/h)
Study: 26821712
Drug: Religiously-tailored HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Religiously-tailored HIV education and testing materials/activities delivered by church leaders (e.g., sermons, brochures/bulletins, testimonials)
Study: 22958024
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3.5 g kg(‐1) per day)
Study: 15693916
Drug: mMMDT 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: mMMDT 80 mg/kg/day
Study: 15693916
Drug: mMMDT 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: mMMDT 40 mg/kg/day